Tuesday, July 1, 2025 7/1/2025

ReCAPSE: Recurrence from Claims And PROs for SEER Enhancement

Award Number: UH3CA218909
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/25/2017
PERIOD OF PERFORMANCE END DATE: 12/31/2024

Group Awards By:

View Award Description

ReCAPSE: Recurrence from Claims And PROs for SEER Enhancement - PROJECT SUMMARY The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute serves as a national dashboard for cancer surveillance and is an authoritative resource for cancer incidence and mortality rates. However, the registry lacks information on cancer recurrence, which is a major outcome impacting decisions and policies around management of disease at both the individual and the population levels. The goal of the proposed study is to develop a scalable approach for population-based ascertainment of cancer recurrence with a specific focus on breast cancer. The first (UG3) phase of the study will develop an innovative algorithm for detecting a first recurrence by combining medical claims with patient reported outcomes (PROs). This phase will be conducted in collaboration with the Seattle-Puget Sound SEER registry and will leverage ongoing research agreements with Puget Sound payers. Different algorithms will be developed to allow for flexibility in maximizing sensitivity or specificity. The algorithms will be validated against gold-standard recurrence information based on electronic medical records from two major local providers. Study participants will consistent of stage I-III breast cancer patients diagnosed in 2013–2016 on whom “gold standard” information on recurrence is available. A retrospective case-control design will be employed in which an equal number of recurrent cases and non-recurrent controls at each validation site will be solicited for PROs regarding their recurrence histories. All validation activities will explicitly adjust for missing data resulting from participant non-response to the PRO solicitation. The second (UH3) phase will be conducted in collaboration with the Kentucky Cancer Registry. The algorithms developed in the UG3 phase will be deployed on all Kentucky stage I-III breast cancer diagnoses in 2015–2017 on whom claims data are available. This phase will include a validation against medical records from patients diagnosed at the University of Kentucky Markey Cancer Center over a concurrent period. In this phase, the study team will develop a visual interface for summarizing recurrence risks overall and within specified prognostic subgroups. The interface will allow users to examine representativeness of the patient cohort used to estimate recurrence risks and will also provide estimates that are adjusted for participant non-response. The proposed work will represent a pioneering effort that establish whether medical claims data combined with patient self-report constitute a promising avenue towards determining whether the critical endpoint of cancer recurrence can be added to population-based cancer registries.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$2,516 )
2025	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Cause and Prevention Research	000	6	5/1/2025	NON-COMPETING CONTINUATION	-$2,516
														Subtotal = -$2,516

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Cause and Prevention Research	001	6	7/9/2024	NON-COMPETING CONTINUATION	$0
2024	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Cause and Prevention Research	000	6	11/7/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Cause and Prevention Research	000	6	11/15/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $567,732 )
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Cause and Prevention Research	006	6	8/4/2022	NON-COMPETING CONTINUATION	$567,732
2022	2021	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Cause and Prevention Research	002	5	5/27/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$193,880
2022	2021	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Cause and Prevention Research	005	5	7/28/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$148,835
2022	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Cause and Prevention Research	000	4	2/1/2022	NON-COMPETING CONTINUATION	$0
2022	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Cause and Prevention Research	001	4	5/27/2022	NON-COMPETING CONTINUATION	-$193,880
2022	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Cause and Prevention Research	004	4	7/28/2022	NON-COMPETING CONTINUATION	-$148,835
2022	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Cause and Prevention Research	003	4	6/28/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $567,732

Issue Date FY: 2021 ( Subtotal = $574,084 )
2021	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Cause and Prevention Research	000	4	6/14/2021	NON-COMPETING CONTINUATION	$574,084
														Subtotal = $574,084

Issue Date FY: 2020 ( Subtotal = $595,136 )
2020	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Biology Research	001	3	8/4/2020	EXTENSION WITH OR WITHOUT FUNDS	$4,550
2020	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Biology Research	000	3	6/25/2020	EXTENSION WITH OR WITHOUT FUNDS	$590,586
														Subtotal = $595,136

Grand Total All Awards = $1,734,436

Top

All Categories

About

Search

Reports

Data Submission

Award Information

ReCAPSE: Recurrence from Claims And PROs for SEER Enhancement

Award Number: UH3CA218909

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/25/2017

PERIOD OF PERFORMANCE END DATE: 12/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer